Thin film cell encapsulation devices

Patent metadata

Field	Value
Publication number	US-10087413-B2
Application number	US-201715713098-A
Country	US
Kind code	B2
Filing date	Sep 22, 2017
Priority date	Mar 23, 2015
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

Thin film devices, e.g., multilayer thin film devices, that encapsulate cells for transplantation into a subject are provided. Also provided are methods of using and methods of preparing the subject devices. The thin film devices include a first porous polymer layer and a second porous polymer layer that define a lumen therebetween and encapsulate a population of cells within the lumen. The thin film devices can promote vascularization into the lumen of the device via the pores in the first polymer layer and/or second polymer layer; limit foreign body response to the device; limit ingress of cells, immunoglobulins, and cytokines into the lumen via the first and the second polymer layers; and release from the first polymer layer and/or the second polymer layer molecules secreted by the population of cells.

First claim

What is claimed is:

1. A device for transplanting a plurality of cells into a subject, said device comprising:
(a) a lumen for enclosing a plurality of cells;
(b) a biocompatible polymer surrounding said lumen and comprising a plurality of pores,
wherein, when said lumen contains insulin-secreting cells, said insulin-secreting cells maintain a glucose stimulation index (GSI) for at least 20 days in vitro of at least 75% of a GSI as measured from Day 1 by a glucose stimulation assay, and
wherein said device has a thickness of less than 40 μm.

2. The device of claim 1 , wherein said plurality of pores are micropores having an average diameter of less than 5 μm.

3. The device of claim 1 , wherein said plurality of pores are micropores having an average diameter of greater than 1 μm.

4. A device for transplanting a plurality of cells into a subject, said device comprising:
(a) a lumen for enclosing a plurality of cells;
(b) a biocompatible polymer surrounding said lumen and comprising a plurality of pores,
wherein, when said lumen contains insulin-secreting cells, said insulin-secreting cells maintain a glucose stimulation index (GSI) for at least 20 days in vitro of at least 75% of a GSI as measured from Day 1 by a glucose stimulation assay, and
wherein said plurality of pores have a connectivity diameter from 100 nm to 900 nm.

5. The device of claim 4 , wherein said glucose stimulation assay comprises: (i) incubating said insulin-secreting cells in 5 mM glucose for 30 minutes; (ii) incubating said insulin-secreting cells in 15 mM glucose for 30 minutes; and (iii) measuring a level of insulin secreted from said insulin-secreting cells in step (i) and step (ii).

6. The device of claim 5 , wherein said GSI is a ratio of said level of insulin secreted from said insulin-secreting cells in step (i) to said level of insulin secreted from said insulin-secreting cells in step (ii).

7. The device of claim 4 , wherein said insulin-secreting cells are MIN6 cells.

8. The device of claim 4 , wherein said plurality of cells, when present in said device, are present in an effective number for treatment of a subject in need thereof.

9. The device of claim 4 , wherein said biocompatible polymer comprises a first layer of biocompatible polymer and a second layer of biocompatible polymer, wherein said lumen is disposed between said first layer of biocompatible polymer and said second layer of biocompatible polymer.

10. The device of claim 9 , wherein said first layer of biocompatible polymer and said second layer of biocompatible polymer comprise the same biocompatible polymer.

11. The device of claim 9 , wherein said first layer of biocompatible polymer and said second layer of biocompatible polymer are each less than 20 μm in thickness.

12. A device of claim 4 , wherein said plurality of pores are nanopores having an average diameter from 5 nm to 500 nm.

13. vThe device of claim 4 , wherein said plurality of pores have an average diameter from 10 nm to 300 nm.

14. The device of claim 4 , wherein said biocompatible polymer is selected from the group consisting of: methacrylate polymer, polyethyleneimine, polyethyleneimine-dextran sulfate, poly(vinylsiloxane) ecopolymerepolyethyleneimine, phosphorylcholine, poly(ethyl methacrylate), polyurethane, poly(ethylene glycol), poly(lactic-glycolic acid), hydroxyapatite, poly(lactic acid), polyhydroxyvalerte and copolymers thereof, polyhydroxybutyrate and copolymers thereof, polycaprolactone, polydiaxanone, polyanhydride, polycyanocrylate, poly(amino acids), poly(orthoesters), polyesters, collagen, gelatin, cellulose polymer, chitosans, alginates, and any combination thereof.

15. The device of claim 4 , wherein said biocompatible polymer comprises polycaprolactone.

16. The device of claim 4 , wherein said device is configured for implantation into a subject.

17. The device of claim 4 , wherein said implantation is selected from the group consisting of: subcutaneous, omentum, intraperitoneal, and intramuscular implantation.

18. The device of claim 4 , wherein said subject is a mammal.

19. The device of claim 4 , wherein said subject is a human.

20. The device of claim 4 , wherein said plurality of cells are selected from the group consisting of: bone marrow cells, mesenchymal stem cells, stromal cells, pluripotent stem cells, induced pluripotent stem cells, embryonic stem cells, blood vessel cells, precursor cells derived from adipose tissue, bone marrow derived progenitor cells, intestinal cells, islets, Sertoli cells, beta cells, progenitors of islet cells, progenitors of beta cells, peripheral blood progenitor cells, stem cells isolated from adult tissue, retinal progenitor cells, cardiac progenitor cells, osteoprogenitor cells, neuronal progenitor cells, genetically transformed cells, and any combination thereof.

21. The device of claim 4 , wherein said plurality of cells are autologous cells, allogeneic cells, xenogeneic cells, or any combination thereof.

22. The device of claim 4 , wherein said plurality of cells are insulin-secreting cells.

23. The device of claim 4 , wherein said device is used to treat a subject in need thereof.

24. The device of claim 23 , wherein said subject in need thereof has or is suspected of having diabetes mellitus.

25. The device of claim 4 , wherein said device is used to transplant said plurality of cells into a subject, and wherein said plurality of cells are introduced into said lumen after said device has been implanted into said subject.

26. The device of claim 4 , wherein said device is used to transplant said plurality of cells into a subject, and wherein said plurality of cells are introduced into said lumen before said device has been implanted into said subject.

27. The device of claim 4 , wherein said device is configured to allow release of a therapeutic protein secreted by said plurality of cells from said lumen of said device.

28. The device of claim 4 , wherein said biocompatible polymer substantially prevents ingress of immune cells and immunoglobulins into said lumen.

29. The device of claim 1 , wherein said plurality of pores have a connectivity diameter from 100 nm to 900 nm.

30. The device of claim 4 , having a thickness of less than 40 μm.

Assignees

• Univ California

Inventors

• Desai Tejal Ashwin
• Nyitray Crystal
• Chang Ryan

Classifications

• A61F2/022

  Artificial gland structures using bioreactors (hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36) · CPC title

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• C08G63/08

  Lactones or lactides · CPC title

• A61K9/0024 Primary

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• C12N5/0676

  Pancreatic cells · CPC title